ArticleInfection and immunity2005
A leucine-rich motif targets Pseudomonas aeruginosa ExoS within mammalian cells.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Structural insight into the membrane targeting domain of the Legionella deAMPylase SidD.PLoS pathogens · 2020Article
- Characterization of Pyrin Dephosphorylation and Inflammasome Activation in Macrophages as Triggered by theInfection and immunity · 2019Article
- VopE, aFrontiers in cellular and infection microbiology · 2017Article
- From GFP to β-lactamase: advancing intact cell imaging for toxins and effectors.Pathogens and disease · 2015Review
- The GAP activity of type III effector YopE triggers killing of Yersinia in macrophages.PLoS pathogens · 2014Article
- Effector CD8+ T cells are generated in response to an immunodominant epitope in type III effector YopE during primary Yersinia pseudotuberculosis infection.Infection and immunity · 2014Article
- Article
- Potential of known and short prokaryotic protein motifs as a basis for novel peptide-based antibacterial therapeutics: a computational survey.Frontiers in microbiology · 2014Article
- Domain analyses reveal that Chlamydia trachomatis CT694 protein belongs to the membrane-localized family of type III effector proteins.The Journal of biological chemistry · 2012Article
- Bacterial toxin effector-membrane targeting: outside in, then back again.Frontiers in cellular and infection microbiology · 2012Review
- A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.Infection and immunity · 2012Article
- Unraveling the mechanism of action of a new type III secretion system effector AexU from Aeromonas hydrophila.Microbial pathogenesis · 2010Article
- Toxins from bacteria.EXS · 2010Review
- The membrane localization domain is required for intracellular localization and autoregulation of YopE in Yersinia pseudotuberculosis.Infection and immunity · 2009Article
- The type III secretion system of Pseudomonas aeruginosa: infection by injection.Nature reviews. Microbiology · 2009Review
- Common themes in the design and function of bacterial effectors.Cell host & microbe · 2009Review
- Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.Critical care medicine · 2009Review
- Expression of Pseudomonas aeruginosa toxin ExoS effectively induces apoptosis in host cells.Infection and immunity · 2006Article
- A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells.Infection and immunity · 2006Article
- The role of Type III secretion system in the pathogenesis ofTzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type III cytotoxins contribute to the ability of bacterial pathogens to subvert the host innate immune system. ExoS (453 amino acids) is a bifunctional type III cytotoxin produced by Pseudomonas aeruginosa. Residues 96 to 232 comprise a Rho GTPase activating protein domain, while residues 233 to 453 comprise a 14-3-3-dependent ADP-ribosyltransferase domain. An N-terminal domain (termed the membrane localization domain [MLD]) targets ExoS to the Golgi-endoplasmic reticulum (Golgi-ER) of mammalian cells. This study identifies an amino acid motif that is responsible for the membrane binding properties of the MLD. Deletion mapping showed that the MLD included a symmetrical leucine-rich motif within residues 51 to 77 of ExoS. The terminal dileucines and internal leucines and an isoleucine within the MLD, but not charged or other hydrophobic residues, targeted a reporter protein to the Golgi-ER region of HeLa cells. Mutations of the leucines within the MLD did not affect type III secretion or translocation into HeLa cells but limited the ability of ExoS to ADP-ribosylate Ras GTPases. Mutations of charged residues within the MLD did not affect type III secretion, delivery into HeLa cells, or the ability of ExoS to ADP-ribosylate Ras GTPases. The organization of the leucines within the MLD of ExoS is different from that of previously described leucine-rich motifs but is present in several other bacterial proteins. This implies a role for intracellular targeting in the efficient targeting of mammalian cells by type III cytotoxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.